(Q37701881)

English

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience

scientific article published on 02 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 August 2017

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience (English)

1 reference

Europe PubMed Central

22 August 2017

0 references

1 reference

based on heuristic

inferred from title

11

object named as

Keith T Flaherty

1 reference

Europe PubMed Central

22 August 2017

Jedd D. Wolchok

18

object named as

Jedd D Wolchok

1 reference

Europe PubMed Central

22 August 2017

19

object named as

F Stephen Hodi

1 reference

Europe PubMed Central

22 August 2017

Anita Giobbie-Hurder

7

object named as

Anita Giobbie-Hurder

1 reference

Europe PubMed Central

22 August 2017

Sandra P D'Angelo

14

object named as

Sandra D'Angelo

1 reference

Europe PubMed Central

22 August 2017

Nageatte Ibrahim

9

object named as

Nageatte Ibrahim

1 reference

Europe PubMed Central

22 August 2017

Michael A Postow

3

object named as

Michael A Postow

1 reference

Europe PubMed Central

22 August 2017

5

object named as

Nikhil Ramaiya

1 reference

Europe PubMed Central

22 August 2017

author name string

Jason J Luke

1

1 reference

Europe PubMed Central

22 August 2017

Margaret K Callahan

2

1 reference

Europe PubMed Central

22 August 2017

Emanuela Romano

4

1 reference

Europe PubMed Central

22 August 2017

Mark Bluth

6

1 reference

Europe PubMed Central

22 August 2017

Donald P Lawrence

8

1 reference

Europe PubMed Central

22 August 2017

Patrick A Ott

10

1 reference

Europe PubMed Central

22 August 2017

Ryan J Sullivan

12

1 reference

Europe PubMed Central

22 August 2017

James J Harding

13

1 reference

Europe PubMed Central

22 August 2017

Mark Dickson

15

1 reference

Europe PubMed Central

22 August 2017

Gary K Schwartz

16

1 reference

Europe PubMed Central

22 August 2017

Paul B Chapman

17

1 reference

Europe PubMed Central

22 August 2017

Richard D Carvajal

20

1 reference

Europe PubMed Central

22 August 2017

language of work or name

0 references

publication date

2 August 2013

1 reference

Europe PubMed Central

22 August 2017

1 reference

Europe PubMed Central

22 August 2017

119

1 reference

Europe PubMed Central

22 August 2017

3687-3695

1 reference

Europe PubMed Central

22 August 2017

20

1 reference

Europe PubMed Central

22 August 2017

Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

23 August 2017

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

23 August 2017

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

23 August 2017

Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

23 August 2017

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

23 August 2017

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

23 August 2017

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

23 August 2017

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

23 August 2017

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

23 August 2017

Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

23 August 2017

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

23 August 2017

Incidence of uveal melanoma in the United States: 1973-1997.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

23 August 2017

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

23 August 2017

Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

23 August 2017

Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

28 September 2017

Ipilimumab activity in advanced uveal melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

1 September 2018

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

1 September 2018

Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

1 September 2018

Variates of survival in metastatic uveal melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

1 September 2018

Very long-term prognosis of patients with malignant uveal melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986037

1 September 2018

Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28282

21 January 2018

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/23913718

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23913718

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of MAGE, gp100 and tyrosinase genes in uveal melanoma cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/23913718

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23913718

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23913718

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.28282

1 reference

Europe PubMed Central

22 August 2017

1 reference

Europe PubMed Central

22 August 2017

1 reference

Europe PubMed Central

22 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37701881&oldid=2119053469"